Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Changing therapeutic paradigms in glaucoma management.

R David1

  • 1Allergan, 2525 Dupont Drive, PO Box 19534, Irvine, CA 92623-9534, USA.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary

Glaucoma treatment is evolving beyond lowering intraocular pressure (IOP). New neuroprotective strategies aim to directly shield the optic nerve and retinal ganglion cells (RGCs), preserving vision regardless of IOP levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comments/clarifications to the publication by Xin et al. (2025).

Ecotoxicology and environmental safety·2025
Same author

Low back pain reduces reliance on the segment rotation mechanism for postural control in challenging postural conditions.

Gait & posture·2025
Same author

"There was no services that I could access so I just stayed on the street…using until I went into labour.": A qualitative study of accessibility and cultural safety of services for perinatal substance use in British Columbia, Canada.

Journal of substance use and addiction treatment·2024
Same author

The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort.

Revue neurologique·2024
Same author

[Outcome, quality of life and functional assessment after perineal and external genitalia gangrene].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Remote EPID-based dosimetric auditing using DVH patient dose analysis.

Physics in medicine and biology·2023

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Glaucoma is characterized by optic neuropathy and vision loss, with elevated intraocular pressure (IOP) as a primary risk factor.
  • Traditional glaucoma management focuses on reducing IOP, but pressure-independent mechanisms of optic nerve damage are increasingly recognized.
  • Lowering IOP alone may not be sufficient for long-term vision preservation in all glaucoma cases.

Purpose of the Study:

  • To review emerging neuroprotective therapeutic strategies for glaucoma.
  • To explore novel compounds and drugs that promote retinal ganglion cell (RGC) survival and prevent RGC death.
  • To evaluate the potential of these agents in both conventional and neuroprotective approaches to glaucoma management.

Main Methods:

  • Review of recent preclinical studies on neuroprotective agents in glaucoma models.
  • Analysis of emerging compounds and drugs under investigation for glaucoma treatment.
  • Discussion of the dual role of IOP-lowering and neuroprotective effects of therapeutic agents.

Main Results:

  • Preclinical studies indicate alpha-adrenergic agonists, like brimonidine, offer neuroprotection alongside IOP reduction.
  • New agents demonstrating neuroprotective utility are being investigated for glaucoma efficacy.
  • Evidence suggests a growing potential for therapies that directly protect the optic nerve.

Conclusions:

  • Neuroprotection represents an innovative therapeutic approach for glaucoma, complementing IOP reduction.
  • Directly protecting the optic nerve and RGCs offers a strategy for vision sparing irrespective of glaucoma etiology.
  • Future glaucoma management may involve combined conventional and neuroprotective treatments to preserve visual function.

Related Experiment Videos